International team unearths strong genetic risk factor for type 2 diabetes in Latin American populations - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
International team unearths strong genetic risk factor for type 2 diabetes in Latin American populations Broad Institute researchers and collaborators harness whole-exome sequencing in study of 4,000 Latin Americans; reveal gene variant of strong effect that might guide treatment


International team unearths strong genetic risk factor for type 2 diabetes in Latin American populations

Broad Institute researchers and collaborators harness whole-exome sequencing in study of 4,000 Latin Americans; reveal gene variant of strong effect that might guide treatment

PR Newswire

CAMBRIDGE, Mass. and MEXICO CITY, June 10, 2014 /PRNewswire/ -- In the largest study of its kind published to date, an international team of researchers in Mexico and the United States has discovered a strong genetic risk factor for type 2 diabetes that primarily affects Latin American patients, but is rare elsewhere. The work further characterizes a gene called HNF1A, responsible for a rare, inherited form of diabetes against which a widely available and inexpensive class of drugs is highly effective. The discovery offers important new clues about the population genetics of type 2 diabetes in Latin American populations, and suggests the possibility of tailored treatments based on patients' genetic makeup. The study appears in the June 11 issue of the Journal of the American Medical Association (JAMA).

Although type 2 diabetes is a major public health problem across the globe, Latin American countries carry a disproportionately
               heavy burden (relative rates of type 2 diabetes by country shown in purple above). Broad Institute researchers and their collaborators
               have has discovered a strong genetic risk factor for type 2 diabetes that primarily affects Latin American patients, but is
               rare elsewhere. The work points to a gene called HNF1A.

"We've identified a genetic risk factor that is present in roughly 2 percent of Mexicans with type 2 diabetes, and its effects are substantial — raising a person's risk of developing the disease five fold," said corresponding author, Jose Florez, a Broad Institute associate member, an associate professor of medicine at Harvard Medical School, and an assistant physician in the Diabetes Unit and the Center for Human Genetic Research at the Massachusetts General Hospital. "It's a striking finding, which really underscores the power of the genetic approach."

Although type 2 diabetes is a major public health problem across the globe, Latin American countries carry a disproportionately heavy burden. In Mexico, for example, it is estimated that the disease affects over 14 percent of adults, which is approximately twice the rate in Europeans or white Americans. A number of factors are thought to drive this increased prevalence, including environmental as well as genetic influences.

Several large-scale genomic studies have been conducted to identify the genetic risk factors that contribute to type 2 diabetes. To date, more than 70 genomic regions have been implicated in the disease. However, the majority of these studies have focused on European populations, leaving a sizeable portion of the genomic landscape of the disease unexplored.

An international research team, known as the SIGMA Type 2 Diabetes Consortium, was formed to investigate the genetics of type 2 diabetes in Mexicans and other Latin American populations. In the current study, the team harnessed whole-exome sequencing, a method that decodes the genetic information within protein-coding genes — a relatively small portion of the genome called the "exome." Whole-exome sequencing has the potential to reveal even rare variations in the genetic code that are often not captured by other approaches but are more likely to affect protein function.

This work was conducted as part of the Slim Initiative for Genomic Medicine for the Americas (SIGMA), a joint U.S.-Mexico project funded by the Carlos Slim Foundation through the Carlos Slim Health Institute. SIGMA focuses on several key diseases with particular relevance to public health in Mexico and Latin America, including type 2 diabetes and cancer.

For the JAMA study, the researchers analyzed samples from nearly 4,000 participants, both people with type 2 diabetes and healthy controls, who were of Mexican or other Latin American ancestry. Their top results identified two genes: SLC16A11, which the team previously found to be linked with an increased risk of type 2 diabetes (findings published late last year in the journal Nature), and HNF1A.

The researchers uncovered a mutation within the HNF1A gene that is present in roughly 2 percent of Mexicans with type 2 diabetes, but in only one-tenth as many healthy adults, and is associated with a four- to five-fold increased risk of the disease. This variant of the gene has not been previously associated with the common form of type 2 diabetes, and is most frequently found in Latin American populations or other populations with Native American ancestry.

While the role of the variant is new, the HNF1A gene itself is well understood. When its function is fully disabled, a rare, inherited form of diabetes known as MODY results. MODY, or Maturity Onset Diabetes of the Young, generally emerges earlier than type 2 diabetes, often in the mid-twenties, and occurs even in the absence of pre-existing obesity.

In contrast, the HNF1A mutation identified in the current study, referred to as p.E508K, is thought to be less severe than those responsible for MODY, leaving some residual gene function intact. Patients with type 2 diabetes who carry this milder form are generally indistinguishable from other patients with type 2 diabetes in terms of age of onset and body weight.  

These findings, while shedding new light on the population genetics of type 2 diabetes, raise some important questions about potential treatments — namely, whether drugs that preferentially work in patients with MODY will also work in patients with type 2 diabetes who carry the p.E508K variant. MODY that stems from HNF1A mutations is often successfully treated with a type of drug known as sulfonylurea because patients with MODY are much more sensitive to that drug than to metformin, the first-line drug typically prescribed in common type 2 diabetes.

"This is an outstanding discovery — one that helps explain the epidemic rates of type 2 diabetes in Latin American populations," said Teresa Tusie-Luna, project leader at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran and Principal Investigator at the Biomedical Research Institute, National University of Mexico. "But we must be mindful that, while the finding is associated with high levels of risk for the disease, we still do not know how the mutation behaves and if there is a specific therapeutic method can be safely applied in the clinic for individuals that carry the mutation. There is much more we need to learn."

This work was made possible by a large, multinational consortium that includes:

  • The Boston-based team included researchers from the Broad Institute, Massachusetts General Hospital, and Harvard Medical School. It was led by Florez; David Altshuler, deputy director and chief academic officer at the Broad Institute and a Harvard Medical School professor at Massachusetts General Hospital; and Daniel MacArthur, group leader within the Analytic and Translational Genetics Unit at Massachusetts General Hospital, assistant professor at Harvard Medical School and a researcher at the Broad Institute; the analysis was led by Karol Estrada, a research fellow within the Analytic and Translational Genetics Unit at Massachusetts General Hospital and at the Broad Institute.
  • The Mexico-based team included investigators from Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Instituto de Investigaciones Biomedicas UNAM, led by Teresa Tusie and Carlos Aguilar; the Instituto Nacional de Medicina Genomica (INMEGEN) led by Lorena Orozco; and the Mexico City Diabetes Study led by Clicerio Gonzalez-Villalpando.
  • The Los Angeles-based team included investigators from the Keck School of Medicine of the University of Southern California and was led by Brian Henderson and Christopher Haiman.
  • The Norway-based team included investigators from the University of Bergen and Haukeland University Hospital, and was led by Pal Njolstad.

Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding, and support.

Paper cited:
The SIGMA Type 2 Diabetes Genetics Consortium. "A low frequency variant in HNF1A has a large effect on type 2 diabetes risk in a Latino population." JAMA. June 11, 2014. DOI: 10.1001/jama.2014.6511

About the Broad Institute of MIT and Harvard
The Eli and Edythe L. Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.

Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to http://www.broadinstitute.org.

About Massachusetts General Hospital
Massachusetts General Hospital (www.massgeneral.org), founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $785 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

About the Carlos Slim Foundation
Created in 1986, through social programs of strong impact for the most vulnerable population, the Carlos Slim Foundation has directly benefited more than 36 million people. With a marked sense of social responsibility, efficiency, and proven results, the Foundation has programs on various fields, such as education, health, nutrition, social justice, culture, human development, support on natural disasters, protection and conservation of the environment, and economic development that contribute to improve the quality of life of population of all ages, fostering the development of human capital and generating opportunities for people, their communities, and therefore, their countries.

As part of the Carlos Slim Foundation, the Health Institute has the purpose to generate solutions in order to help solve Mexico's and Latin America's main public health problems focusing on the most vulnerable populations. www.salud.carlosslim.org

 

Broad Institute Logo.

 

Photo - http://photos.prnewswire.com/prnh/20140610/116763
Logo - http://photos.prnewswire.com/prnh/20140520/89735

SOURCE Broad Institute

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here